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Background: It is unknown if treatment with anti-epileptic drugs in children with epilepsy with a presumed 
good prognosis is always necessary. 
Aim: To study the course of newly diagnosed epilepsy in children with a presumed good prognosis who are 
managed without AED treatment.  
Methods: One hundred fifty-one children (one month-12 years of age) with  2-5 lifetime unprovoked 
seizures (excluding febrile convulsions), were followed for three years. Treatment was initially withheld. 
Children with symptomatic epilepsy, absence or myoclonic epilepsy were excluded. AED treatment was 
started after >10 lifetime seizures or an episode of status epilepticus during follow-up, or if the parents or 
treating physician deemed it otherwise necessary. 
Key findings: During follow-up, 113 children continued to meet our criteria for refraining from treatment 
with antiepileptic drugs, yet 30 started treatment at the request of the parents. Thirty-eight children at 
some time met the criteria to start treatment, but the parents of 16 declined treatment. In all, 99 (66%) 
children maintained the no-treatment regime.  Ninety-eight children (65% of 151) reached a terminal 
remission of at least one year, including 83  who did not receive antiepileptic drug treatment (84% of the 
untreated 99).  Mean terminal remission was significantly longer in the group with a total of <10 seizures 
compared to those with >10 seizures. Treatment did not increase the length of terminal remission. Adverse 
events, including traumatic injury, occurred equally in the treated and in the untreated children. Measures 
of Quality of Life suggested a better outcome in those without treatment. 
Conclusions: Children with newly diagnosed epilepsy with a presumed good prognosis may not need 
immediate AED treatment. Postponing treatment does not alter the chance of remission or the risk of 







Epilepsy can be diagnosed after two or more unprovoked seizures.  Epidemiological evidence indicates that 
in children with a first unprovoked seizure the risk of a second is approximately 50% (Stroink et al., 1998).  
After a second seizure, the risk for additional seizures increases to approximately 75-85% (Camfield et al., 
1985; Shinnar et al., 2000), justifying the diagnosis of epilepsy. Once the diagnosis of epilepsy in children 
has been made, it is common practice to start treatment with anti-epileptic drugs (AEDs) with the 
exception of self-limited (benign) focal syndromes. However, only 28% of those with >2 seizures will have 
more than 10 seizures during the next 10 years (Shinnar et al., 2000). Moreover, prospective cohort studies 
of newly diagnosed childhood epilepsy have found that the outcome in selected untreated children was 
excellent (Camfield et al., 1993; Arts et al., 2004). In the Dutch study, 14% were not treated with AEDs and 
>90% of these were in long-term remission after 12 to 18 years of follow-up (Geerts et al., 2010). These 
studies suggest that many children with epilepsy have only a few seizure recurrences and may not need 
AED treatment for what appears to be a self-limited disorder. On the basis of findings like these it has been 
suggested more than 20 years ago that AEDs do not alter the prognosis of epilepsy, but instead only help 
to prevent seizures (Shinnar and Berg, 1996). 
In the Nova Scotia (Canada) and Dutch cohort studies, the decision to start AED treatment was 
pragmatically taken by the treating physician and the patient’s family. Combining these two cohorts 
allowed the development of prognostic models which predicted a good outcome (terminal remission) with 
a positive predictive value of about 0.7 (Geelhoed et al., 2005). Variables predictive of a good outcome 
were idiopathic epilepsy of all types, cause unknown focal epilepsy, small number of seizures before 
initiation of AED, later age at onset and absence of neurological and/or intellectual deficit. We reasoned 
that it might be possible at the time of diagnosis to identify children for whom a more conservative 
approach to starting treatment would be justified. Obviously, this approach would need to balance the risk 
of further seizures versus the advantage of avoiding AEDs with their risk of adverse events and the burden 
of daily medication. Several studies help to justify delaying AED treatment. First, in the Nova Scotia study, 
the long term outcome did not vary with the number of pre-treatment seizures provided their number was 
<10 (Camfield et al., 1996). Secondly, several studies support the contention that a few additional seizures 
do not lead to cognitive deterioration (Verity, 1998; Schouten et al., 2002; Oostrom et al., 2003). 
The study reported here was the logical consequence of this reasoning, and followed directly from the 
above mentioned Canadian and Dutch studies. Our hypothesis was that omitting or postponing AED 
treatment in children with a good prognosis at the time of diagnosis of childhood-onset epilepsy would not 
negatively influence the epilepsy outcome, nor significantly increase the risk of accidents and adverse 




2.1 Inclusion and exclusion criteria: This was a prospective study of one hundred sixty-three 
consecutive children with newly diagnosed epilepsy recruited from the inpatient and outpatient 
departments of 11 hospitals. Patients were enrolled between 2000 and 2006 in three university and seven 
general hospitals in the Netherlands and one university hospital in Canada, and followed for three years. 
All participating physicians were experienced paediatric epileptologists and all had participated in the 
earlier studies (noted above).  Patients were included if they had ,  <5 lifetime seizures (excluding febrile 
convulsions and with at least 2 unprovoked seizures within the 12-month period before enrolment) , were 
between 1 month and 12 years of age, and had idiopathic (genetically determined) generalized or focal 
epilepsies or focal epilepsy cause unknown and  no significant neurological and/or intellectual deficit. Two seizures 
within 24 hours with complete recovery after each seizure were considered separate events. Children with 
a single episode of non-febrile status epilepticus (defined as a seizure continuing for at least 30 minutes, or 
several seizures with a total duration of at least 30 minutes without regaining consciousness in-between 
the seizures, the usual definition at that time) were also included. .  Exclusion criteria were >5 seizures 
before intake, symptomatic aetiology such as progressive brain or metabolic disorder, any clinical or 
radiological signs of brain damage, structural brain abnormalities identified with CT or MRI that could be 
linked to the epilepsy, or intellectual disability (clinically defined as IQ < 70). The following epilepsy 
syndromes were also excluded: any absence or myoclonic epilepsy, and the syndromes of Ohtahara, West, 
Lennox-Gastaut, Doose, Dravet and Landau-Kleffner/CSWS. Other reasons for exclusion included: history of 
neonatal convulsions; treatment with an AED in the past except for treatment of non-epileptic disease; 
ongoing treatment with an AED for a non-epileptic disorder; ongoing disease that might have influenced 
the outcome measures; acute symptomatic aetiology (except for a history of febrile convulsions); children 
or caregivers not able to comply with the study protocol or not able to understand its essential features.  
2.2 Treatment strategies: The primary intention was not to start AED treatment until the end of follow-up 
(FU) unless there was an episode of status epilepticus or a 10th lifetime unprovoked seizure. AED treatment 
could also be initiated at the request of the child, parents/caregivers or attending physician for any reason 
(e.g. fear of further seizures, unacceptable number or severity of seizures, accident due to a seizure, or 
other concerns).  
When treatment was initiated, monotherapy with one of the first-line drugs was used (target dosages: 
carbamazepine 10-15 mg/kg, clobazam 0.3-0.5 mg/kg, lamotrigine 4-6 mg/kg, and valproate 20-30 mg/kg). 
An AED was introduced over four weeks except for lamotrigine, which was introduced at a slower rate. 
Treatment was individualized with the expectation that it would be tapered and discontinued after one to 
two years of seizure freedom.  
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2.3 Evaluation: The following baseline variables were gathered in all participating children: gender, age, 
body weight, number of seizures and the dates of occurrence, date of diagnosis, EEG and imaging results. 
EEG results (available for analysis in 148 out of the 151 children) were classified as normal (including mild 
abnormalities), more than mildly abnormal background-pattern, epileptic or epileptiform abnormalities 
(generalized, focal, unclassifiable, specific epilepsy syndrome), or other non-epileptiform abnormalities. 
After complete evaluation (including MR or – if not possible – CT), seizure type, aetiology, and epilepsy 
syndrome were classified by the treating physician and reviewed by the first two authors, both at entry to 
the study and after three years of FU. 
Children were prospectively followed in the outpatient departments for three years from the date of 
diagnosis at 3, 6, 12, 18, 24, 30, and 36 months. At each visit, the treating physician documented the interim 
history and completed both the physical examination and a questionnaire regarding seizures, medication (of 
any type and for any indication), and adverse events. The child and parent/caregiver completed 
questionnaires about symptoms and adverse events (each visit), seizure severity (0, 6, 18, 36 month visits) 
and quality of life (QoL; 0, 6, 18, 36 month visits). For the parental and child questionnaires, we used the 
modified Hague scale for symptoms and side-effects (SSS) (Carpay et al., 1996; Geerts et al., 2010) and the 
Impact of Paediatric Epilepsy Scale (IPES) (Camfield et al, 2001). The SSS asks for the presence (mild, 
moderate or serious) or absence of 27 complaints that had occurred during the course of the epilepsy, 
whether caused by the epilepsy itself or by the treatment (supplementary table 1). The IPES contains a visual 
analogue scale (Likert Scale) of QoL ranging from 1 (poor) to 6 (excellent) and 11 questions that assess the 
impact of epilepsy on academic achievement, participation in activities, health, relationship with family and 
with peers and siblings, social activities, self-esteem, the relation between the parents, social life and 
parental hopes for their child’s future.  
If AED treatment was started, the reason for abandoning the no-treatment policy was recorded. After 
three years of FU, the physician re-evaluated the classification of the aetiology and of the epilepsy 
syndrome and verified if the child was, was not or had been receiving AED treatment.  
2.4 Definitions: Adverse events (AEs) were defined as any undesirable experience including accidents or 
diseases occurring to the child during the study period, whether or not considered related to the current 
treatment policy. All AEs reported spontaneously by the child or the parents or observed by the treating 
physician were recorded on an AE data collection form. The intensity of these AEs was graded by the 
physician on a four-point scale defined as: mild (discomfort noticed but no disruption of normal daily 
activity), moderate (discomfort sufficient to reduce or affect normal daily activity), severe (inability to 
perform daily activities), or serious (SAE: any adverse event that was fatal, life-threatening, disabling or 
required in-patient hospitalization, prolonging of hospitalization or caused a malignancy). SAEs were 
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immediately reported to the study coordinator and to the local Ethics Review Board. For each AE, the 
relationship to treatment policy (definite, probable, possible, unknown, definitely not) as judged by the 
treating physician as well as the actions taken were recorded.  
Terminal remission (TR) was defined as the interval between the last seizure and the end of FU. 
2.5 Outcome measures: The main outcome measure was the proportion of untreated children after three 
years of FU. The TR at the end of FU was also determined as well as the number of untreated children who 
had a TR of at least 12 months, and the number of seizures during FU.  
In the treated group, the delay between study entry and the initiation of treatment, the reason to start 
treatment and the TR after three years were recorded. To establish better predictability for the no-
treatment option, the untreated and the treated groups were compared to identify differences in the 
collected intake and early follow-up variables.  
The analyses at the end of the three-year FU were also intended to identify possible unfavourable 
consequences in the no-treatment group. To this end, we analysed the differences between the treated 
and the untreated groups in terms of number of seizures experienced during the FU and after the start of 
AED, as well as the accidents and adverse events, the – possibly drug-related – complaints and the quality 
of life as described above.  
2.6 Statistical analyses: The data was analysed using SPSS Version 20 software. A Kaplan-Meier survival 
curve of the proportion of children left untreated was constructed from baseline to 36 months. Univariate 
and multivariate analyses of the differences between the untreated and the treated groups at baseline and 
after 6-month FU were performed.  The differences in outcome (terminal remission) between the treated 
and untreated groups were analysed with Analysis of Variance (ANOVA) statistics. 
To test for differences between groups in number of seizures before intake, the non-parametric Mann-
Whitney U test was used. Pearson Chi-Square Test or Fisher’s Exact Test were used to test for differences 
when categorical variables were evaluated. 
The analysis of the Impact of Paediatric Epilepsy Scale (IPES) and the QoL visual analogue scale included 
the General Linear Model (GLM) Repeated Measures analysis, allowing both between-subjects and within-
subject analysis of repeatedly measured variables at intake and the 6, 12, 18 and 36 months FU visits. For 
missing values, imputation by using means was applied if they had completed the scales at least three 
times. A significance level of 0.05 was used for all statistical tests.  
2.7 Ethical approval for this study was obtained from the ethics review boards of all participating hospitals. 





3.1 Description of the cohort: Five of the 163 recruited children began medication at the request of their 
parents within 1-4 days after the diagnosis of epilepsy and therefore were not considered to have 
remained untreated. They were not followed further. Seven children were followed for <3 years; two of 
these started medication after their 10th seizure and five had <10 seizures and had not started an AED at 
the time of last contact. The mean FU of these seven children was 1.9 years (median: 2.0, range: 1.15-
2.86). Consequently, 151 remained initially untreated, completed the three-year FU and were available for 
analysis. Table 1 (column Entire cohort) shows baseline demographic characteristics and the epilepsy 
classifications at intake and after three years of FU of these 151 children, and supplementary table 2 the 
characteristics of the initial seizures before diagnosis.  
After three years, the classification of the epilepsy changed in 44 children (29%; table 1). The cohort 
contained three major groups of epilepsy syndromes: self-limited focal epilepsies (n=28 at intake, 35 after 
reclassification at 3 years FU), focal epilepsy cause unknown (45 at intake, 39 after 3 years) and genetic 
generalized epilepsy with tonic-clonic seizures (TCS) only (54 at intake, 44 after 3 years). At intake 25, and 
after 3 years 24 children could not be classified because of lack of specific generalized or focal features. In 
seven children (4.0%), the initial epilepsy type or syndrome diagnosis was revised in such a way that they 
would have met the exclusion criteria, if the correct diagnosis would have been made at intake (one benign 
myoclonic epilepsy of infancy, one juvenile myoclonic epilepsy,  five a change from cause unknown to 
symptomatic epilepsy [one Lennox-Gastaut syndrome, one proven and one probable Dravet syndrome, 
one undetermined but with the development of intellectual disability during FU and one symptomatic focal 
epilepsy – a child with an initially undiscovered cortical dysplasia]). In three patients the diagnosis of 
epilepsy was rejected (they had either reflex syncope or cardiovascular syncope). These ten children were 
retained in the analysis according to the ‘intention to treat’ principle. Thirty-one children had had 
convulsions associated with a febrile illness before enrolment. Six of them also had febrile seizures during 
FU. Additionally, 10 children without febrile convulsions before intake had seizures with fever during FU.  
3.2 Treatment initiation: All 151 children were initially left untreated with AEDs and followed 
prospectively.  Figure 1 presents the number untreated during follow-up as a Kaplan-Meier survival curve. 
At one year after enrolment the cumulative proportion remaining off medication was 79.5% (95% CI: 73.0-
86.0), at two years 70.2% (95% CI: 62.9-77.5) and at three years 65.6% (95% CI: 58.0-73.2).  
Fifty-two children started AED treatment (valproic acid 25, carbamazepine 23, lamotrigin 2, clobazam 2) 
after study entry; 37 children remained on monotherapy, 15 used multiple AEDs. Reasons for starting AEDs 
during follow-up were the occurrence of ≥10 seizures (n=20), status epilepticus (n=2) or a parental request 
to start medication earlier than the 10th seizure  because of fear for additional seizures or increasing 
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severity of the seizures (n=30; figure 2).  The mean interval between enrolment and start of medication in 
these 52 children was 338 days (median: 291; range 7-1076). The time to start of AED did not differ 
between children with focal epilepsy, generalized epilepsy with TCS only, or epilepsy with  focal and 
generalized seizures combined (p=0.56). Neither was the treatment delay related to the number of 
seizures prior to enrolment (on the basis of the inclusion criteria, this could vary between 2 and 5; 
p=0.973).  
Four groups emerged:  group A (n=22) consisted of children treated with AED according to the protocol 
(after >10 seizures or an episode of status epilepticus); group B (n=30) of children treated before a 10th 
seizure; group C (n=16) of children continuing without AED treatment despite >10 seizures; group D (n=83) 
of children completing 3 years of FU without AED treatment according to the protocol. In sum, 97 children 
(64.2%) had <10 seizures between epilepsy onset and the end of follow-up. The strategy of not starting 
AED treatment was achieved in 83 of these 97 (85.6%). Fifty-four children had >10 seizures of whom 16 
(29.6%) continued without AED treatment at parental request (group C; figure 2). 
Table 1 also shows the characteristics of these four groups at the time of initial diagnosis. Only a few 
significant differences were noted. Children who ultimately experienced >10 seizures (groups A and C) 
were more likely to have had 4 or 5 seizures before intake (p =0.043). Group D was less likely to have an 
abnormal EEG than the other three groups (p=0.054), and group B was more likely to show generalized 
spike-wave discharges while the other three groups had predominantly focal abnormalities (p=0.009).  
3.3 Terminal remission and number of seizures: Thirty-six (23.8%) children had no further seizures during 
the entire FU and another 36 (23.8%) had their last seizure within the first year after intake.  
Ninety-eight children (64.9%) reached a TR of >1 year, 83 of them (54.3%) without AED treatment at 36 
months (73 from group D, 4 from group C and 6 from groups A and B together; in the latter 6, the AED had 
already been withdrawn). Figure 3A shows the cumulative proportion of children attaining a TR of at least 
one year. The mean TR at the end of three years of FU was 1.7 years (95% CI: 1.5; 1.9; median: 1.9; range: 
0.0-3.0). However, the four groups differed significantly. Those with >10 seizures or SE, (group A, treated, 
group C, untreated), had the shortest TR and group D (untreated according to protocol) had the longest 
remission (p<0.001; Table 2). Figure 3B differentiates the cumulative probability of reaching a 1-year TR for 
the four groups.  
The duration of TR was not significantly different between the three major syndrome groups (self-limited 
focal, focal cause unknown and genetic with TCS only) (table 1).   
Most children had a limited number of seizures. A notable exception occurred in the treated groups, in 
which the proportion of children with >15 seizures was clearly higher than the proportion with a smaller 
number (Supplementary Figure). This is only partly explained by the fact that these contained the five 
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children in which the original epilepsy syndrome diagnosis had been incorrect and was modified to a type 
of symptomatic focal or generalized epilepsy. 
3.4 Accidents, injuries and other adverse events (AEs): Before enrolment, 20 children (13.2%) had 
experienced >1 complication, accident or injury as a result of a seizure. Nineteen of the 23 reports (83%) 
concerned head injuries. The intensity was reported as mild (n=12), moderate (n=5) and severe (n=2, one 
cerebral concussion and one hospitalization).  
During FU, 58 children reported a total of 91 AEs of all kinds. Thirteen (in 10 children) were classified as 
SAE’s (table 3A). All SAE’s involved hospitalizations. Three were seizure-related; one was already treated 
with AED at the time of the SAE, one was hospitalized because of postictal drowsiness and another 
because of a SE; both started AED on the day of the hospitalization. Seven additional children were 
hospitalized for disorders unrelated to the epilepsy. No deaths occurred. 
More specifically, accidents and injuries were reported 56 times by 37 children (table 3B). One was 
classified as SAE, but it could not be definitely determined whether this accident (a fall with serious head 
trauma) was due to a seizure. Eight were considered to be severe, 13 moderate and 34 mild. Twenty-three 
accidents (41.1%) were considered to be seizure-related, in two the cause was unclear. Of note, 12 of the 
23 children with a seizure-related accident were at that time not receiving AED treatment.  
Non-accidental AEs were reported 35 times by 25 children. Only two of these were seizure-related. An 
association with AED treatment at the time of the AE could not be found either: 24 were reported while 
the child was not receiving AEDs, two during AED treatment and for nine the treatment status at the time 
of the incident was unclear.  
3.5 Symptoms, impact of epilepsy and quality of life: As noted in the methods, at each visit the families 
completed a check list of neurological and general symptoms.  This check list did not attempt to relate 
symptoms to seizures or AED treatment.  Therefore, we analysed the number of symptoms noted at each 
visit, subtracting the number of symptoms at baseline. The mean number of symptoms compared to 
baseline did not vary significantly between the four groups (p=0.101) nor throughout the clinical course 
(p=0.101), nor between the groups receiving one of the four AEDs mentioned in the protocol.   
The IPES includes one single question for assessing global QoL. Parents are asked to rate the quality of life 
of their child on a Likert scale from 1 (poor) to 6 (excellent). We compared this global measure at intake 
and at the 6, 18 and 36-month visits. The between-subjects analysis revealed a significant difference 
between the groups, the groups without AED treatment having a better Likert Scale QoL (p=0.006, Figure 
4). These findings were largely confirmed by analysis of the answers to the other 11 questions of the IPES. 
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For eight of the questions, there were significant differences between the groups, most often with a 






It is common practice to withhold AED treatment in children with a single unprovoked seizure. We are of 
the impression that an increasing number of clinicians refrain from treatment in children with only a few 
solitary seizures, notably in self-limited epilepsy with centrotemporal spikes and other syndromes with a 
known good outcome. Until now the evidence to justify this approach has been limited. The only study 
known to the present authors in which immediate and delayed treatment have been compared is the 
MESS study (Marson et al., 2005). In this study, both adult- and childhood-onset patients were followed, 
and the authors did not distinguish between patients with one solitary seizure or multiple seizures.  In the 
present study, we have systematically and prospectively examined a no-treatment approach in a selected 
group of children newly diagnosed with epilepsy with characteristics suggesting a high likelihood of a self-
limited course.  
4.1 General cohort. The no-treatment strategy was successful in 83 out of 151 children (group D, 55.0%) in 
the sense that they did not start AED treatment and had <10 seizures and no episodes of status epilepticus 
during the three years of FU. Nearly all children in this group had at least one year of terminal remission – 
a self-limited course without AED treatment. The clinical course of the remainder of the cohort was more 
complex with some families choosing AED treatment after fewer than 10 seizures and others having >10 
seizures but choosing to continue without treatment. 
In the overall cohort, almost two thirds of the children were seizure-free in the last year of follow-up (TR 
>1yr: 64.9%). This is comparable with other outcome studies, but it might have been higher after longer 
follow-up, as the natural course of childhood epilepsy may require more than two years to reach seizure-
freedom. In addition, many of the children without remission during the third year of follow-up had only 
rare seizures with long inter-seizure intervals (data not shown). Based on this data in children fulfilling our 
entry criteria, postponement of AED treatment seems to be justified. On the other hand, the outcome 
prediction by our entry criteria was far from perfect since 38 children had >10 seizures, and 10 had >20. 
Therefore, to be certain that a strategy of omitting or postponing AED therapy is justified on the basis of 
the selection criteria used in this study (in our opinion the best we have at the moment), we also needed 
to demonstrate that postponement of treatment did not harm our patients. 
4.2 No treatment vs. treatment. The patients in group D had by definition <10 seizures from the onset of 
their epilepsy until the end of follow-up, and those in groups A and C had >10 seizures or an episode of 
status epilepticus. Overall, the children with >10 seizures, whether treated or untreated, were less likely to 
have a substantial terminal remission. Even though this confirms earlier findings by Camfield et al [8], our 
results also suggest that the natural course of the epilepsy, but not AED treatment, determines the seizure 
outcome, at least in this relatively small cohort with its specific entry criteria. This tends to confirm the  
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contention that AED medications do not alter the chance of remission – they are anti-seizure and not anti-
epileptic medications. Reassuringly, we found that the time to the onset of a >1 year TR was the same in 
groups A and C.  Both groups had ≥10 seizures but Group A was then treated with AEDs and Group C 
continued without treatment (Figure 3B).  In these children also, AED treatment did not seem to influence 
the chance or timing of a TR.  We conclude that from a seizure remission perspective, our avoidance or 
delay in AED treatment was not harmful. These findings are comparable with those of the MESS study 
(Marson et al., 2005), in which the long-term outcome of the group with immediate and the one with 
deferred treatment was largely equal. 
4.3 Is delay of treatment detrimental? Beyond seizure recurrence, we were concerned that a no AED or 
delayed AED treatment approach might lead to more injuries from seizures. About two-thirds of reported 
injuries were not related to seizures. Of the seizure-related injuries about one-half were in untreated 
patients. It is possible that AED treatment might have prevented a few of these injuries. Fortunately, none 
of the “serious accidents” were definitely related to a seizure.  
Complaints other than accidents and injuries could have been caused both by continuing seizures as well 
as by side-effects of the AED. Our analyses show that there was no clear pattern or trend in the number of 
symptoms when compared to baseline throughout the eight visits of the study. Surprisingly, we did not 
find an increase of complaints in children on AED treatment, despite the fact that we used a pre-formatted 
questionnaire to detect side-effects at each visit to the outpatient clinic.  
Somewhat in contrast with this, parents considered the general QoL of their children to be better when 
they were not treated with AED, and this did not change during FU. Possible explanations are the absence 
of AED-related side-effects and, perhaps more likely, the smaller number of seizures that most of these 
children had. We conclude that whichever treatment strategy was followed, the FU did not reveal any 
improvement or deterioration in injuries, complaints or QoL that could be related to the treatment 
strategy.  
A final issue to be considered with either no or delayed treatment is the risk of SUDEP. There were no 
deaths in this 3-year cohort study. Parental and physician concerns about SUDEP are vital in the decision to 
start or delay AED treatment. Fortunately, a combined study of four large population-based cohorts 
(n=2239) found that seizure-related death or SUDEP was exceedingly rare in childhood-onset epilepsy 
(Berg et al., 2013). In “uncomplicated” childhood epilepsy, the overall risk of death was the same as in the 
general population. In a long-term study from Finland, there were no deaths within 5 years of epilepsy 
onset and none under 14 years of age in the idiopathic and cryptogenic epilepsy groups (Sillanpää and 
Shinnar, 2010).  Therefore, our findings are reassuringly consistent with the extremely low risk of SUDEP in 
the childhood-onset epilepsy types that we studied.   
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4.4 Limitations of this study. Our study has some limitations. First of all, this was not a randomized 
controlled study. When we began this study, it was designed to be randomized with the entry and 
exclusion criteria as mentioned in the Methods section. We had intended to compare the outcomes of 
initially untreated children with those of children treated from the moment of diagnosis. This plan failed 
because after reading the information leaflet and hearing the explanation from the treating physician, 
almost all parents refused to consent to randomization and preferred the no-treatment option. After 
recruiting only 40 children over several years, we concluded that a randomized trial was simply not 
feasible, so our project became a prospective follow-up cohort study. The lack of randomization may have 
introduced some bias in decisions taken during the FU, and interpretation of the results. 
Secondly, our sample size may have been too small to detect small effects of the no-treatment strategy, in 
particular the very small risk of SUDEP in self-limited childhood epilepsies (as noted above).  
Many families chose not to follow the protocol and to start AEDs before 10 seizures or to continue without 
AED treatment despite >10 seizures. Apparently, there are strong parental opinions about the benefits and 
risks of drugs in countries like Canada and The Netherlands. In group B (treated before 10 seizures), there 
were more patients with generalized epilepsy with generalized tonic-clonic seizures only with a 
predominance of generalized spike wave on the initial interictal EEG. The perceived impact of generalized 
seizures on the children and their parents  may have stimulated this group to ask for AED treatment before 
10 seizures. The strategy of delayed AED treatment is apparently more palatable to families of children 
with other types of seizures.    
A further limitation was that reports by the children themselves or information on their behaviour and 
school performance were not systematically collected during this study and Quality of Life was not 
extensively assessed. However, we had the impression that QoL was better in children who did not use 
AED, and deterioration of behaviour or school performance was not reported by any parent. It is uncertain 
whether this is the result of the no-treatment policy. Alternatively, children with a better QoL may have 
been more likely to remain untreated (as noted above). 
Finally, the duration of follow-up was limited to three years. The possibility of long-term remission after 
longer FU could not be excluded in children with a TR <1 year. Therefore, we presume that an increased 
duration of FU would have strengthened our results. 
The FU of the cohort described here was concluded in 2009. Unforeseen circumstances delayed the 
publication of the results. However, we think that the results remain important and confirm earlier findings 
indicating that  treatment at the time of the initial diagnosis of childhood epilepsy with a high likelihood of 
a self-limited course may be safely omitted or at least postponed. To our knowledge, a study like this has 
not been performed elsewhere.  Since 2009, several newer AEDs have become available that may have 
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fewer side effects than those on the market when we started our study. It is conceivable that this might 
have altered parents’ interest in a no-treatment strategy.  
 
4.5 General conclusions. Based on this study, we  believe there is a group of children with newly 
diagnosed epilepsy in whom AED treatment can be safely withheld without the risk of a negative impact on 
the epilepsy itself or the QoL of the children. Our findings indicate that in this “epilepsy-only” group of 
patients predicted to have a self-limited course, the chance of remission is, apparently, not determined by 
AED treatment. However, current knowledge does not enable us to identify these children at intake with 
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Table 1. Characteristics of the 151 children at intake and after three years of follow-up [n (%)] 
 




to protocol  





















Total number 151 22 30 16 83  
Boys 87 (58) 
p=0.073 
13 (59) 14 (47) 11 (69) 49 (59) P=0.499 
















































History of febrile convulsions 31 (21) 6 (27) 6 (20) 4 (25) 15 (18) P=0.772 
Positive family history for 
epilepsy 1st degree (n=148) 




• More than mildly 
abnormal background 
pattern or other non-
epileptic abnormalities 
 Epileptic +/- other 
abnormalities  
 Generalized 








































































Classification of the epilepsy 
at intake: 
Self-limited focal epilepsies 
 




epilepsies with TCS only 
  
Epilepsies without 







































































Classification of the epilepsy 
after 3 years: 
Self-limited focal epilepsies 
 
Focal epilepsy, cause 
unknown 
Idiopathic generalized 
epilepsies with TCS only 
Benign myoclonic epilepsy of 
infancy 
Juvenile myoclonic epilepsy 
Epilepsy with myoclonic-
astatic seizures 
Symptomatic focal epilepsies 
 
Epilepsies without 






























































































* p is based on nonparametric test, ** p is based on the Contingency Coefficient  
TCS = tonic-clonic seizures  
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TR >1 yr 
N (%) 
Mean TR 
95% CI (yrs) 
Group A: >10  seizures and treated 
(according to protocol) 
22 5 (23) 
0.65 
0.36 – 0.95 
Group B: treated before 10th seizure 30 16 (53) 
1.35 
0.92 – 1.77 
Group C: not treated despite >10 seizures 16 4 (25) 
0.66 
0.24 – 1.08 
Group D: <10 seizures and not treated 
(according to protocol) 
83 73 (88) 
2.31 
2.12 – 2.51 
Total 151 98 (65) 
1.71 
1.52 – 1.89 
 
For number of children with TR >1 year: p=0.000  











Table 3A: Serious adverse events leading to hospitalization (n = 13) 
Nature of SAE AED treatment 
at time of SAE 
2x hospitalization because of serious immunodeficiency 
and cytomegalovirus infection 
no 
3x hospitalization: first for tonsillectomy and ear drums, 
then because of pharyngitis with dehydration, and 
seven months later because of a generalized infection 
with mycoplasma pneumonia 
no 
Streptococcal tonsillitis  no 
Tonsillectomy unknown 
Tonsillectomy no 
Gastro-enteritis with dehydration no 
Acute psychotic episode no 
Fall while at school, seizure uncertain  yes 
Status epilepticus no 






Table 3B: Types of accidents / injuries during follow-up 
 




Total Severe Seizure-related 
Untreated at time of 
injury 
Soft tissue injuries 26 0 14 7/14 
Laceration 3 0 1 0/1 
Dental injury 1 0 1 1/1 
Head injury 18 2 5 + 1 unknown 4/6 
Any other fracture 7 6 0  
Fall in water 1 0 1 unknown 0/1 





Supplementary Table 1. The Hague Scale for Symptoms and Side-effects (SSS; Carpay et al 1996) 





1  Drowsiness, sleepiness     
2  Dizziness     
3  Unsteady when walking     
4  Falling     
5  Sickness     
6  Constipation     
7  Diarrhoea     
8  Shaking, trembling     
9  Speech difficulties     
10  Double or blurred vision     
11  Headache     
12  Fatigue     
13  Loss of appetite     
14  Depression     
15  Hyperactivity     
16  Temper tantrums, 
aggression 
    
17  Slowness     
18  Poorer school results     
19  Decreased concentration     
20  Behavioural disturbance     
21  Weight gain     
22  Weight loss     
23  Hair loss     
24  Excessive hair growth     
25  Drooling     
26  Gingival disease (gums)     






Supplementary table 2. Characteristics of the seizures occurring before intake 
 
1st seizure 2nd seizure 3rd seizure 4th seizure 5th seizure 
No. of children 151 151 85 (56%) 38 (25%) 12 (8%) 
Last seizure before intake 
 
16 (11%) 35 (23%) 26 (17%) 12 (8%) 






























Type of seizure 
Focal with intact awareness 
Focal with impaired 
awareness 
Focal to bilateral tonic-clonic  





















































Figure 1: Kaplan-Meier survival curve of the cumulative proportion of children remaining without AED-



































>= 10 seizures < AED 
n=20  (38.5%)




< 10 seizures during 3y-FU 
n=47 (74.6%)
< 10 seizures < AED 
n=30 (57.7%)
Status Epilepticus  < AED 
n=2  (3.8%)
< 10 seizures during 3y-FU 
n=36 (100%)
>=10 seizures during 3y-FU 
n=20 (100%)
< 10 seizures during 3y-FU 
n=1 (50.0%)
< 10 seizures during 3y-FU 
n=13 (43.3%)
>=10 seizures during 3y-FU 
n=17 (56.7%)









Figure 3A: Kaplan-Meier survival curve of the cumulative proportion of children reaching a 1-year 









Figure 3B: Kaplan-Meier survival curve of the cumulative proportion of the children in each of the 4 
groups reaching a terminal remission of at least one year 
Group A (>= 10 seizures, treatment according to protocol), Group B (<10 seizures, earlier treatment on 
request), Group C (>=10 seizures, request to continue the no-treatment policy), Group D (<10 seizures, no 
treatment according to protocol).  




















Supplementary Figure: Total number of non-febrile seizures experienced until the end of follow-up 
Group A (treatment according to protocol), Group B (earlier treatment on parental request), Group C 
(elected to continue the no-treatment policy despite 10 or more seizures), Group D (no treatment 
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